Factors Associated with the Decision to Decline Chemotherapy in Metastatic Non-Small Cell Lung Cancer.

chemotherapy disparities in cancer care lung cancer refusal of treatment

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
09 Mar 2023
Historique:
received: 01 02 2023
revised: 02 03 2023
accepted: 08 03 2023
medline: 30 3 2023
entrez: 29 3 2023
pubmed: 30 3 2023
Statut: epublish

Résumé

(1) Background: Disparities in cancer treatment and outcomes have long been well-documented in the medical literature. With the eruption of advances in new treatment modalities, the long-existing disparities are now being further uncovered and brought to the attention of the medical community. While social health determinants have previously been linked to treatment disparities in lung cancer, we analyzed data from the National Cancer Database to explore sociodemographic and geographic factors related to accepting or declining physician-recommended chemotherapy. Patients diagnosed with metastatic lung cancer between 2004 and 2016 who declined chemotherapy recommended by their physicians were included in this study. Multivariate logistic regression analysis was performed. Cox Regression and Kaplan-Meier analyses were performed to look for survival characteristics. (2) Results: 316,826 patients with Stage IV lung cancer were identified. Factors related to a higher rate of refusal by patients included older age > 70, female sex, low income, lack of insurance coverage, residency in the New England region, and higher comorbidity. Patients living in areas with lower education were less likely to decline chemotherapy. (3) Conclusion: Further understanding of the factors impacting treatment decisions would be essential to improve the efficacy of care delivery in patients with cancer and reduce reversible causes of disparity.

Identifiants

pubmed: 36980573
pii: cancers15061686
doi: 10.3390/cancers15061686
pmc: PMC10046757
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Thorax. 1996 Jun;51(6):564-8
pubmed: 8693434
J Natl Cancer Inst. 2016 Oct 20;109(2):
pubmed: 27754926
Am J Public Health. 2020 Oct;110(S3):S292-S293
pubmed: 33001721
South Med J. 2017 Jan;110(1):47-53
pubmed: 28052175
Cancer. 2011 Jul 15;117(14):3242-51
pubmed: 21264829
Asian Pac J Cancer Prev. 2013;14(10):6173-80
pubmed: 24289644
JAMA Oncol. 2021 Dec 01;7(12):1824-1832
pubmed: 34673888
Cancer. 2015 Jun 15;121(12):2020-8
pubmed: 25917222
J Oncol Pract. 2018 Oct 24;:JOP1800120
pubmed: 30355027
MMWR Morb Mortal Wkly Rep. 2014 Jun 13;63(23):505-10
pubmed: 24918485
J Clin Oncol. 1997 Jan;15(1):330-40
pubmed: 8996160
Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):366-72
pubmed: 15006910
Expert Rev Anticancer Ther. 2016 Jun;16(6):653-60
pubmed: 27010977
Psychooncology. 2009 May;18(5):483-9
pubmed: 18942662
Cancer. 2018 Nov 1;124(21):4181-4191
pubmed: 30475400
J Pain Symptom Manage. 2001 Sep;22(3):727-37
pubmed: 11532586
Cancer Manag Res. 2019 Jan 21;11:943-953
pubmed: 30718965
JCO Oncol Pract. 2022 Sep;18(9):e1417-e1426
pubmed: 35658495
J Natl Cancer Inst. 2019 Feb 1;111(2):189-200
pubmed: 30085213
J Community Health. 2017 Apr;42(2):324-332
pubmed: 27678390
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Oncology (Williston Park). 2009 Apr 15;23(4):369-75
pubmed: 19476267
J Clin Oncol. 2011 Jun 10;29(17):2319-26
pubmed: 21555700
Oncol Nurs Forum. 2004 Mar-Apr;31(2):313-9
pubmed: 15017447
Lancet Oncol. 2008 Mar;9(3):222-31
pubmed: 18282806
J Natl Cancer Inst. 2015 Dec 11;108(5):
pubmed: 26657334
Am J Prev Med. 2015 Dec;49(6 Suppl 5):S489-97
pubmed: 26590644
Breast Care (Basel). 2015 Apr;10(2):95-100
pubmed: 26195937
J Support Oncol. 2003 Nov-Dec;1(4 Suppl 2):18-24
pubmed: 15346996
Am J Med. 2018 Oct;131(10):1187-1199.e5
pubmed: 29906429
Clin Lung Cancer. 2020 May;21(3):e115-e129
pubmed: 31570228
J Oncol Pract. 2015 Mar;11(2):79-113
pubmed: 25784575
J Racial Ethn Health Disparities. 2016 Dec;3(4):555-564
pubmed: 27294749
Cancer Treat Rev. 2015 Feb;41(2):197-215
pubmed: 25579752
Med Care. 2016 May;54(5):490-7
pubmed: 26900834
Mayo Clin Proc. 2019 Aug;94(8):1623-1640
pubmed: 31378236
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
Thorac Cancer. 2017 Sep;8(5):443-450
pubmed: 28627788
J Natl Compr Canc Netw. 2016 May;14(5):539-50
pubmed: 27160232
Lung. 2020 Dec;198(6):897-907
pubmed: 33175991
Am J Surg. 2020 Dec;220(6):1605-1612
pubmed: 32680623
N Engl J Med. 2002 Apr 4;346(14):1061-6
pubmed: 11932474

Auteurs

Iktej Singh Jabbal (IS)

Department of Hematology/Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA.

Saad Sabbagh (S)

Department of Hematology/Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA.

Mira Itani (M)

Department of Hematology/Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA.

Barbara Dominguez (B)

Department of Hematology/Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA.

Mohamed Mohanna (M)

Department of Hematology/Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA.

Valencia Henry (V)

OMS-II, Edward Via College of Osteopathic Medicine-Carolinas Campus, Spartanburg, SC 29303, USA.

Hong Liang (H)

Department of Clinical Research, Cleveland Clinic Florida, Weston, FL 33331, USA.

Diana Saravia (D)

Department of Hematology/Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA.

Tiffany George (T)

Department of Hematology/Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA.

Zeina Nahleh (Z)

Department of Hematology/Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA.

Evan Alley (E)

Department of Hematology/Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA.

Rafael Arteta-Bulos (R)

Department of Hematology/Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA.

Classifications MeSH